Literature DB >> 3653181

VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group.

P Dombernowsky1, J Buesa, H M Pinedo, A Santoro, H Mouridsen, R Somers, V Bramwell, M Onsrud, J Rouesse, D Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3653181     DOI： 10.1016/0277-5379(87)90324-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  5 in total

1.  Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma.

Authors:  J D Licht; R Mazanet; P J Loehrer; R Gonin; K H Antman
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide.

Authors:  G Saeter; K Talle; O P Solheim
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.

Authors:  Sheetal Sharma; Shweta Takyar; Stephanie C Manson; Sarah Powell; Nicolas Penel
Journal:  BMC Cancer       Date:  2013-08-13       Impact factor: 4.430

4.  EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma.

Authors:  H J Keizer; D Crowther; O S Nielsen; A T Oosterom; J H Muguiro; C V Pottelberghe; R Somers; T Tursz
Journal:  Sarcoma       Date:  1997

5.  A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma.

Authors:  C R Crawley; I R Judson; M Verrill; C Hill; F I Raynaud
Journal:  Sarcoma       Date:  1997
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.